Q2 Earnings Forecast for Cingulate Issued By Zacks Research

Cingulate Inc. (NASDAQ:CING) – Stock analysts at Zacks Research issued their Q2 2026 earnings per share estimates for shares of Cingulate in a research report issued to clients and investors on Tuesday, May 19th. Zacks Research analyst J. Vandermosten anticipates that the company will earn ($0.59) per share for the quarter. The consensus estimate for Cingulate’s current full-year earnings is ($1.88) per share. Zacks Research also issued estimates for Cingulate’s Q3 2026 earnings at ($0.57) EPS, Q4 2026 earnings at ($0.54) EPS and FY2028 earnings at ($1.06) EPS.

Several other brokerages have also recently issued reports on CING. Ascendiant Capital Markets decreased their target price on shares of Cingulate from $58.00 to $55.00 and set a “buy” rating on the stock in a research report on Wednesday, April 8th. Wall Street Zen lowered Cingulate from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th. Roth Mkm reissued a “buy” rating and set a $10.00 price objective on shares of Cingulate in a research note on Tuesday. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Cingulate in a research report on Monday, April 20th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Cingulate has a consensus rating of “Hold” and an average target price of $32.50.

Cingulate Stock Up 5.5%

CING stock opened at $4.63 on Thursday. Cingulate has a 52 week low of $3.20 and a 52 week high of $11.89. The firm has a market capitalization of $61.49 million, a P/E ratio of -1.09 and a beta of -0.81. The company has a fifty day simple moving average of $6.11 and a two-hundred day simple moving average of $5.32.

Cingulate (NASDAQ:CING) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.42).

Institutional Investors Weigh In On Cingulate

Hedge funds and other institutional investors have recently made changes to their positions in the company. XTX Topco Ltd purchased a new position in shares of Cingulate during the 4th quarter worth about $90,000. Quadrature Capital Ltd bought a new position in Cingulate during the 4th quarter valued at about $66,000. Kestra Advisory Services LLC raised its position in Cingulate by 29.8% in the 4th quarter. Kestra Advisory Services LLC now owns 122,000 shares of the company’s stock worth $529,000 after purchasing an additional 27,979 shares during the period. DRW Securities LLC bought a new stake in Cingulate in the fourth quarter worth about $255,000. Finally, Geode Capital Management LLC boosted its position in shares of Cingulate by 43.9% during the fourth quarter. Geode Capital Management LLC now owns 61,035 shares of the company’s stock valued at $265,000 after buying an additional 18,629 shares during the period. Hedge funds and other institutional investors own 41.31% of the company’s stock.

About Cingulate

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.